Mesothelin-targeted bispecific antibodies drive synthetic agonistic receptor – Transduced T cells to mediate specific and conditional therapy of human pancreatic cancer models. (March 2018) - Benmebarek, M.; Karches, C.; Schmidbauer, M.; Kurzay, M.; Klaus, R.; Geiger, M.; Rataj, F.; Cadilha, B.; Keyl, J.; Lesch, S.; Heise, C.; Murr, R.; et al.